NCT03787758View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

October 7, 2019

Study Completion Date

October 7, 2019

Conditions
Huntington Disease
Interventions
DRUG

SAGE-718

SAGE-718

Trial Locations (2)

90806

Sage Investigational Site, Long Beach

08053

Sage Investigational Site, Marlton

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03787758 - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | Biotech Hunter | Biotech Hunter